In principle, mRNA vaccines are ideal for health emergencies as they can be quickly mass produced using a template. The problem is that current cell-based template production methods take too long, ...
In a turbulent market environment, Moderna Inc (BMV:MRNA). shares have touched a 52-week low, sinking to $30.7, with concerning financial metrics showing negative EBITDA of $2.36 billion and gross ...
Moderna has been ordered to pay almost £44,000 after 12-year-olds were encouraged to join Covid vaccine trials with the ...
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $34 from $41 and keeps an Underperform rating on the shares ...
Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...
O n Friday, February 7, a hearing took place in the Montana state legislature on a bill that would ban the use of mRNA vaccines in humans. The bill was sponsored by State Representative Greg Kmetz ...
We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...
To come up with last week’s worst performers, we considered only the stocks with at least $2 billion in market capitalization ...
AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...
Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for ...